Botulinum Neurotoxins in Neurological Disorders
Summary
Botulinum neurotoxins are potent bacterial proteins that inhibit neurotransmitter release by cleaving components of the vesicle fusion machinery at synapses. Originally identified as the cause of flaccid paralysis in botulism, these toxins have been harnessed as precision therapeutics in a wide range of neurological conditions, including dystonia, spasticity, chronic migraine and focal pain syndromes. Advances in structural biology and molecular engineering have expanded the repertoire of serotypes and subtypes, offering tailored tools that bind distinct neuronal receptors and exhibit variable durations of action. Concurrently, emerging data reveal central nervous system effects via retrograde transport and microglial activation, prompting careful evaluation of long-term safety. Research on receptor interactions, signalling pathways governing neuromuscular junction regeneration and immunogenicity profiles underscores the global significance of botulinum neurotoxins as both therapeutic agents and models for synaptic biology.
Research from Nature Portfolio
Recent structural studies have elucidated how full-length synaptic vesicle glycoprotein 2A (SV2A) engages the receptor-binding domain of botulinum neurotoxin type A2 alongside antiepileptic ligands, revealing a dual binding site that informs the rational design of next-generation therapies and neuroimaging tracers. The high-resolution cryo-EM maps illustrate protein–protein and glycan interactions that stabilise toxin docking, while comparative analysis of derivative compounds explains differential binding affinities. In addition, the discovery of a novel serotype, tentatively named BoNT X, has reshaped our understanding of substrate specificity: this toxin cleaves canonical VAMP isoforms at a unique junction and extends activity to non-canonical SNARE proteins, offering a new platform for modulating intracellular trafficking and secretory processes in research and potential clinical applications.
Botulinum Neurotoxins in Neurological Disorders publication trend
The graph below shows the total number of articles in botulinum neurotoxins in neurological disorders across all publications each year (not limited to Nature Index journals).
Technical terms
Botulinum neurotoxin: A family of bacterial proteins that block acetylcholine release at nerve terminals by cleaving SNARE proteins, causing muscle relaxation.
Serotype: A classification of botulinum neurotoxin based on antigenic differences, reflecting distinct amino acid sequences and substrate specificities.
Synaptic vesicle glycoprotein 2A (SV2A): A membrane protein in synaptic vesicles that serves as a receptor for certain botulinum neurotoxins and antiepileptic drugs.
SNARE complex: A set of proteins (including VAMP, SNAP-25 and syntaxin) that mediate the docking and fusion of synaptic vesicles with the presynaptic membrane.
Neuromuscular junction (NMJ): The synapse between a motor neuron and a skeletal muscle fibre where neurotransmission controls muscle contraction.
Microglia: Resident immune cells of the central nervous system that respond to infection, injury or inflammatory signals.
Retrograde axonal transport: The process by which materials and proteins move from the nerve terminal back to the neuronal cell body along microtubules.
Insulin-like growth factor 1 receptor (IGF1R): A cell-surface receptor tyrosine kinase that regulates cell growth, differentiation and neuromuscular junction regeneration.
References
- Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A. Nature Communications (2024).
- Identification and characterization of a novel botulinum neurotoxin. Nature Communications (2017).
- Botulinum Neurotoxin Induces Neurotoxic Microglia Mediated by Exogenous Inflammatory Responses. Advanced Science (2024).
- Blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-A treatment. Cell Death & Disease (2023).
- Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacological Reviews (2017).
- Botulinum Neurotoxins A and E Undergo Retrograde Axonal Transport in Primary Motor Neurons. PLOS Pathogens (2012).
- Immunogenicity of botulinum toxins. Journal of Neural Transmission (2012).
- Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments. Toxins (2012).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.